MYX is continuing to grow its revenue and profits which looks...

MYX is continuing to grow its revenue and profits which looks very promising going forward. In fact Revenue for the 1HFY2016 came in at $127.3M which is around what MYX had for the full year in 2014 and again in 2015.

The 1HFY16 RESULT were excellent but IMO may have seemed stronger when you compare them to the same period last year as sales and profit were challenging because of the lack of sales from Doryx 200mg.

I was pleased the Doryx 50mg prescriptions grew from 500 to 1500 per week which is an excellent result as they still have exclusivity and was a larger increase as a percentage than the Doryx 200mg which grew from 4500 prescriptions to 5000 per week.

MYX is still looking actively at further acquisitions and will progress its many generic products under FDA for approval such as dofetilide capsules which MYX said should be this calendar year.

MYX has done an exceptionable job over the last 2 years from its acquisitions and growth from its products. Still see it as a long term hold with plenty of upside ahead.

Cheers Matsim